Predicting Effectiveness of Light Treatment for Winter Seasonal Affective Disorder

November 19, 2019 updated by: Teodor Postolache, University of Maryland, Baltimore

Predicting Light Treatment's Effectiveness on Reducing Depression and Cardiovascular Risk in Seasonal Affective Disorder

This study will evaluate a possible tool for predicting future effectiveness of bright light in treating seasonal affective disorder, winter subtype, and will examine secondary effects of bright light on cardiovascular risk factors.

Study Overview

Status

Completed

Conditions

Detailed Description

The winter subtype of seasonal affective disorder (SAD) is characterized by episodes of major depression in the fall and winter, with remission of these episodes in the spring and summer. SAD disrupts the lives of millions of Americans, who experience symptoms such as restless agitation, increased appetite and weight gain, and reduced energy and motivation. Bright light treatment, while shown to be effective in improving SAD in 75% of cases, only causes a full remission in 50% of cases. If doctors had a diagnostic tool to determine which patients would respond to bright light therapy, they could make better decisions about whether to prescribe bright light as treatment. This study will examine a possible diagnostic tool-a single, 1-hour bright light session-for predicting improvement in SAD symptoms over an extended course of bright light treatment. Additionally, because many symptoms of SAD (like weight gain and sedentary lifestyle) correspond to cardiovascular risk, this study will examine whether bright light treatment correlates with improved cardiovascular health.

Participants with SAD will be randomly assigned to first receive a 1-hour session of either bright light or the placebo, red light. Then all participants will switch and receive a 1-hour session of the other type of light. Red light has been accepted as a placebo in previous SAD studies because it does not suppress melatonin or shift circadian rhythms. Before and after each light session, participants will have their SAD symptoms evaluated in a clinical interview and self-report measure. After these two light sessions, all participants will receive instructions for administering bright light treatment on their own at home. For the next 6 weeks, participants will administer the bright light to themselves for 1 hour every morning. Every week they will undergo clinical interviews by phone and will mail in self-report measures, some completed daily and some weekly, to the researchers. The participants will have checkups and interviews in person on Weeks 4 and 6. At the two time periods, SAD symptoms and indicators of cardiovascular risk, such as appetite and sleep loss, will be evaluated. The participant responses to bright light and red light at the initial session will be compared with the participant responses to the subsequent 6-week treatment.

Study Type

Observational

Enrollment (Actual)

41

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 64 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with history of recurrent winter depression

Description

Inclusion Criteria:

  • Current major depressive disorder, by structured diagnostic interview (SCID), or current bipolar II disorder, if no prior history of rapid cycling, by SCID
  • Prior history of major depressive disorder or bipolar II disorder with seasonal specifier, by SCID
  • Score of 21 or greater on Hamilton Rating Scale for Depression - Seasonal Affective Disorder Version (SIGH-SAD), met at three time points (informed consent session, 24 hours prior to first light therapy session, and at first light therapy session)

Exclusion Criteria:

  • Current bipolar I disorder, psychotic disorder, or cognitive disorder, by SCID
  • Illicit drug use in the past year, by self-report, or alcohol abuse by SCID
  • History of systemic lupus erythematosus
  • History of heart attack or stroke
  • No antidepressant, mood stabilizer, or antipsychotic medication treatment 30 days before treatment
  • Current occupation involves shift work
  • Current sensitivity to bright light or vision problems not correctable by glasses, by self-report
  • Inability to distinguish colors or see stars at night because of increased light sensitivity, by self-report
  • Current suicidal ideation, by self-report during SCID interview
  • Women of childbearing potential who are pregnant, nursing, or trying to become pregnant. Female participants of childbearing potential must agree to one of the following types of birth control: oral, transdermal, or implantable hormonal contraceptives; intrauterine device; diaphragm plus spermicide; or female condom plus spermicide.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
A
Participants will be given a 1-hour lab test of bright light treatment, then the bright light treatment for 6 weeks.
One hour of exposure to bright light daily upon awakening for 6 weeks.
Other Names:
  • Brite light III light box (Apollo) 10,000 lux.
B
Participants will be given a 1-hour treatment of the red light placebo, then the bright light treatment for 6 weeks.
One hour of exposure to red light.
Other Names:
  • Dim red light box (Apollo) 50 lux.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Hamilton rating scale for depressional seasonal affective disorder (SIGH SAD)
Time Frame: Measured at baseline, 1 hour after light treatment, and weekly for 6 weeks
Measured at baseline, 1 hour after light treatment, and weekly for 6 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Hunger questionnaire
Time Frame: Measured daily for 6 weeks
Measured daily for 6 weeks
Three factor eating questionnaire
Time Frame: Measured weekly for 6 weeks
Measured weekly for 6 weeks
Sleep log
Time Frame: Measured weekly for 6 weeks
Measured weekly for 6 weeks
Food craving questionnaire
Time Frame: Measured daily for 6 weeks
Measured daily for 6 weeks
Side effects questionnaire
Time Frame: Measured weekly for 6 weeks
Measured weekly for 6 weeks
Adherence questionnaire
Time Frame: Measured weekly for 6 weeks
Measured weekly for 6 weeks
Profile of Mood States
Time Frame: Measured at baseline, 1 hour after light treatment, and weekly for 6 weeks
Measured at baseline, 1 hour after light treatment, and weekly for 6 weeks
Beck Depression Inventory-II (BDI)
Time Frame: Measured at baseline, 1 hour after light treatment, and weekly for 6 weeks
Measured at baseline, 1 hour after light treatment, and weekly for 6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Teodor T. Postolache, MD, University of Maryland, Baltimore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2007

Primary Completion (Actual)

April 1, 2010

Study Completion (Actual)

August 1, 2010

Study Registration Dates

First Submitted

August 25, 2008

First Submitted That Met QC Criteria

August 25, 2008

First Posted (Estimate)

August 27, 2008

Study Record Updates

Last Update Posted (Actual)

November 21, 2019

Last Update Submitted That Met QC Criteria

November 19, 2019

Last Verified

November 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • HP-00043574
  • DSIR 83-ATSO (National Institute of Mental Health)
  • R34MH073797 (U.S. NIH Grant/Contract)
  • H-28845

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe